HC Wainwright Increases Monopar Therapeutics (NASDAQ:MNPR) Price Target to $125.00

Monopar Therapeutics (NASDAQ:MNPR) had its price target lifted by equities researchers at HC Wainwright from $105.00 to $125.00 in a research note issued on Wednesday, MarketBeat.com reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 18.26% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Chardan Capital reissued a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a research note on Monday, March 30th. UBS Group set a $105.00 price target on Monopar Therapeutics in a research note on Monday, June 29th. Finally, Zacks Research upgraded Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Monopar Therapeutics has an average rating of “Buy” and an average target price of $112.08.

Monopar Therapeutics Trading Down 6.0%

Monopar Therapeutics stock opened at $105.70 on Wednesday. The company has a market cap of $708.19 million, a PE ratio of -55.63 and a beta of 1.46. Monopar Therapeutics has a 1 year low of $29.18 and a 1 year high of $116.64. The company’s 50-day moving average is $79.49 and its two-hundred day moving average is $66.36.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.41. Research analysts forecast that Monopar Therapeutics will post -2.82 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new stake in Monopar Therapeutics in the third quarter valued at approximately $28,000. BNP Paribas Financial Markets boosted its position in shares of Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Monopar Therapeutics during the fourth quarter worth $65,000. JPMorgan Chase & Co. grew its holdings in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Monopar Therapeutics in the 2nd quarter valued at $80,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.